ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FUM Futura Medical Plc

40.50
1.70 (4.38%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.70 4.38% 40.50 39.70 40.50 40.00 39.00 39.60 309,491 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -20.62 120.28M

Futura Medical PLC MED2002 Update (3021P)

16/11/2016 7:00am

UK Regulatory


Futura Medical (LSE:FUM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Futura Medical Charts.

TIDMFUM

RNS Number : 3021P

Futura Medical PLC

16 November 2016

For immediate release 16 November 2016

Futura Medical plc

("Futura" or "the Company")

MED2002 Update

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the outcome of the detailed analysis of the results of the recent breakthrough clinical study of MED2002, its topical gel for erectile dysfunction ("ED"), and to outline the Company's strategy for the further development of the product following the Company's recent fundraising.

Since the announcement of the clinical results on 7 September 2016, the Company has conducted extensive sub-analysis of the clinical data. The clinical study used one dosage of the active principle, 0.6mg of glyceryl trinitrate, and produced highly statistically significant results in the mild ED patient group.

The sub-analysis has also showed statistically significant results in the mild to moderate group and also suggests that an increased strength dose, 1.2mg of glyceryl trinitrate, may increase the gel's efficacy especially in the moderate and severe ED patient groups.

All the existing oral medications for ED offer at least two dose strengths to treat the different levels of ED severity experienced by patients. Futura intends to adopt a similar treatment strategy to optimise MED2002's potential commercial and therapeutic benefits.

In parallel with ongoing out-licensing negotiations, the Company is planning a further Phase III clinical programme for MED2002, which will start recruiting patients following discussions in early 2017 with EU and US regulators. It is intended that the clinical programme will include two dosage strengths of MED2002's active principle: 0.6 mg and 1.2mg of glyceryl trinitrate.

James Barder, Futura's Chief Executive, commented: "We believe the strategy of including two dosages of MED2002 in the remaining clinical development program to potentially treat as wide a range of ED sufferers as possible will maximise the potential of this breakthrough ED treatment.

"This strategy is also mindful that, with MED2002's rapid speed of onset and favourable safety profile, two dose strengths may unlock the huge potential of an over the counter treatment in an indication where only one in three men are prepared to go to a doctor to seek treatment. The lower dosage of MED2002 could potentially address the over the counter market whilst the higher dose would be prescription only."

For further information please contact:

 
 Futura Medical plc 
 James Barder, Chief Executive              Tel: +44 (0) 1483 685 
                                             670 
 Email to: james.barder@futuramedical.com   www.futuramedical.com 
 
 N+1 Singer (Nominated 
  Adviser and Broker) 
 Aubrey Powell / Liz Yong                   Tel:+44 (0) 20 7496 3000 
 
 For media enquiries please 
  contact: 
 Buchanan 
 Mark Court / Sophie Cowles                 Tel: +44 (0) 20 7466 
  / Stephanie Watson                         5000 
 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKADBABDKQDD

(END) Dow Jones Newswires

November 16, 2016 02:00 ET (07:00 GMT)

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Your Recent History

Delayed Upgrade Clock